Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A28555 | 11438497 | Gastroenterology | Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. | 2001 | Details |
| A28556 | 11433896 | Obes Surg | Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? | 2001 | Details |
| A28559 | 11422610 | J Gastroenterol Hepatol | Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. | 2001 | Details |
| A28562 | 11251303 | Hepatol Res | Influence of TT virus on the histopathological features of nonalcoholic fatty liver disease. | 2001 | Details |
| A28565 | 10902968 | Liver | The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. | 2000 | Details |
| A28568 | 10599403 | Acta Gastroenterol Latinoam | [Steatohepatic cirrhosis in a morbidly obese patient]. | 1999 | Details |
| A28573 | 10048738 | Scand J Gastroenterol | The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. | 1999 | Details |
| A28577 | 9647594 | Mod Pathol | Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. | 1998 | Details |
| A28582 | 8563007 | Ital J Gastroenterol | Non-alcoholic steatohepatitis. Report of five cases and review of the literature. | 1995 | Details |
| A28584 | 7533231 | Liver | Cytokeratin inclusions in alcoholic liver disease and their relation to the amount of alcohol intake. | 1994 | Details |
| A28585 | 8052745 | Rev Invest Clin | [Non-alcoholic fatty liver: 10 years' experience at the Insituto Nacional de la Nutrición Salvador Zubirán]. | 1994 | Details |
| A28586 | 8974350 | Alcohol Alcohol Suppl | Pathological spectrum of alcoholic liver disease. | 1994 | Details |
| A28587 | 7658998 | Medicina (B Aires) | [Non alcoholic steatohepatitis]. | 1994 | Details |
| A28591 | 7691125 | Eur J Morphol | Contributions of light and transmission electron microscopy to the study of the human fat-storing cell. | 1993 | Details |
| A28594 | 1490801 | Int J Clin Pharmacol Ther Toxicol | Pharmacokinetics of trapidil (Rocornal) in patients with chronic liver disease. | 1992 | Details |
| A28595 | 1526433 | Gastroenterol Jpn | Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. | 1992 | Details |
| A28597 | 1782374 | J Gastroenterol Hepatol | Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. | 1992 | Details |
| A28608 | 35243535 | Langenbecks Arch Surg | Expanding donor pool for live donor liver transplantation: utilization of donors with non-alcoholic steatohepatitis after optimization. | 2022 | Details |
| A28618 | 35226336 | J Endocrinol Invest | Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH). | 2022 | Details |
| A28622 | 35219165 | Int Immunopharmacol | Targeted inhibition of the immunoproteasome blocks endothelial MHC class II antigen presentation to CD4+ T cells in chronic liver injury. | 2022 | Details |
| A28625 | 35217809 | Acta Pharmacol Sin | FXR: structures, biology, and drug development for NASH and fibrosis diseases. | 2022 | Details |
| A28636 | 35212988 | Methods Mol Biol | Mouse Bone Marrow Cell Isolation and Macrophage Differentiation. | 2022 | Details |
| A28644 | 35194060 | Sci Rep | Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. | 2022 | Details |
| A28645 | 35192632 | PLoS One | Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. | 2022 | Details |
| A28647 | 35189618 | Pharmacology | Docosahexaenoic Acid Attenuates the Progression of Nonalcoholic Steatohepatitis by Suppressing the Adipocyte Inflammation via the G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 Pathway. | 2022 | Details |
| A28665 | 35167910 | J Hepatol | Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis. | 2022 | Details |
| A28693 | 35121372 | Biochem Biophys Res Commun | Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. | 2022 | Details |
| A28704 | 35113139 | Diabetes Care | Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes. | 2022 | Details |
| A28708 | 35110697 | Acta Pharmacol Sin | NASH: regulatory considerations for clinical drug development and U.S. FDA approval. | 2022 | Details |
| A28715 | 35102596 | Hepatology | Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis. | 2022 | Details |
| A28717 | 35101153 | Inflamm Regen | A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice. | 2022 | Details |
| A28724 | 35092721 | J Control Release | Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. | 2022 | Details |
| A28725 | 35092323 | J Magn Reson Imaging | Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis. | 2022 | Details |
| A28733 | 35085894 | Biochem Biophys Res Commun | Liver cyclophilin D deficiency inhibits the progression of early NASH by ameliorating steatosis and inflammation. | 2022 | Details |
| A28740 | 35076966 | Hepatology | Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. | 2022 | Details |
| A28744 | 35074532 | Clin Gastroenterol Hepatol | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. | 2022 | Details |
| A28753 | 35065262 | Ann Hepatol | Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/Smad3 signaling pathways. | 2022 | Details |
| A28755 | 35058729 | J Ginseng Res | Oral administration of Jinan Red Ginseng and licorice extract mixtures ameliorates nonalcoholic steatohepatitis by modulating lipogenesis. | 2021 | Details |
| A28763 | 35039610 | Lab Invest | High-fat diet-induced nonalcoholic steatohepatitis is accelerated by low carnitine and impaired glucose tolerance in novel murine models. | 2022 | Details |
| A28783 | 35006626 | Hepatology | Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through endothelial nitric oxide synthase. | 2022 | Details |
| A28784 | 35006616 | Hepatology | The RSPO-LGR4/5-ZNRF3/RNF43 module in liver homeostasis, regeneration, and disease. | 2022 | Details |
| A28794 | 34999207 | Clin Gastroenterol Hepatol | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. | 2022 | Details |
| A28795 | 34997987 | Hepatology | NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH. | 2022 | Details |
| A28817 | 34944770 | Biomedicines | Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells. | 2021 | Details |
| A28821 | 34940991 | Hepatology | A strategy of vascular-targeted therapy for liver fibrosis. | 2021 | Details |
| A28834 | 34923653 | Hepatology | Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. | 2022 | Details |
| A28846 | 34917911 | JHEP Rep | ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. | 2021 | Details |
| A28852 | 34910547 | Sci Transl Med | β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. | 2021 | Details |
| A28855 | 34907360 | Acta Pharmacol Sin | Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. | 2021 | Details |
| A28865 | 34890841 | Cell Mol Gastroenterol Hepatol | Sphingosine 1-Phosphate Receptor 4 Promotes Nonalcoholic Steatohepatitis by Activating NLRP3 Inflammasome. | 2021 | Details |
| A28870 | 34884600 | Int J Mol Sci | New Therapeutic Targets for Hepatic Fibrosis in the Integrin Family, α8β1 and α11β1, Induced Specifically on Activated Stellate Cells. | 2021 | Details |
| A28894 | 34856227 | J Control Release | Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. | 2021 | Details |
| A28895 | 34855620 | J Clin Invest | Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. | 2022 | Details |
| A28906 | 34843960 | Pharmacol Res | Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases. | 2021 | Details |
| A28936 | 34797360 | Food Funct | Effects of Salvia hispanica L. (chia) seed on blood coagulation, endothelial dysfunction and liver fibrosis in an experimental model of Metabolic Syndrome. | 2021 | Details |
| A28944 | 34790547 | Endosc Int Open | Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. | 2021 | Details |
| A28956 | 34781165 | Redox Biol | The sex steroid precursor dehydroepiandrosterone prevents nonalcoholic steatohepatitis by activating the AMPK pathway mediated by GPR30. | 2021 | Details |
| A28968 | 34765422 | Australas J Ultrasound Med | Performance of shear wave elastography: A single centre pilot study of mixed etiology liver disease patients with normal BMI. | 2021 | Details |
| A28972 | 34760013 | Res Pharm Sci | Attenuating effects of allantoin on oxidative stress in a mouse model of nonalcoholic steatohepatitis: role of SIRT1/Nrf2 pathway. | 2021 | Details |
| A28973 | 34757037 | J Genet Genomics | Tumor necrosis factor-α signaling in nonalcoholic steatohepatitis and targeted therapies. | 2021 | Details |
| A28974 | 34755957 | Dermatol Online J | Evaluating the association of central centrifugal cicatricial alopecia (CCCA) and fibroproliferative disorders. | 2021 | Details |
| A29001 | 34719550 | Yakugaku Zasshi | [PPARα-Ligand Binding Modes Revealed by X-ray Crystallography]. | 2021 | Details |
| A29002 | 34716927 | Hepatology | Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. | 2021 | Details |
| A29007 | 34712137 | Front Pharmacol | Micronized Palmitoylethanolamide Ameliorates Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis via Inhibiting Inflammation and Restoring Autophagy. | 2021 | Details |
| A29025 | 34687329 | Abdom Radiol (NY) | Liver fibrosis assessment: MR and US elastography. | 2021 | Details |
| A29029 | 34676758 | J Proteome Res | Nontargeted Serum Lipid Profiling of Nonalcoholic Steatohepatitis by Multisegment Injection-Nonaqueous Capillary Electrophoresis-Mass Spectrometry: A Multiplexed Separation Platform for Resolving Ionic Lipids. | 2021 | Details |
| A29095 | 34572384 | Biomedicines | Modelling Nonalcoholic Steatohepatitis In Vivo-A Close Transcriptomic Similarity Supports the Guinea Pig Disease Model. | 2021 | Details |
| A29108 | 34545586 | Hepatology | The transcription factor zinc fingers and homeoboxes 2 alleviates NASH by transcriptional activation of phosphatase and tensin homolog. | 2022 | Details |
| A29151 | 34503196 | Cancers (Basel) | Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. | 2021 | Details |
| A29167 | 34482560 | Hepatology | Melanoma differentiation-Associated gene 5 protects against NASH in mice. | 2021 | Details |
| A29183 | 34441565 | Foods | White Button Mushroom Extracts Modulate Hepatic Fibrosis Progression, Inflammation, and Oxidative Stress In Vitro and in LDLR-/- Mice. | 2021 | Details |
| A29196 | 34430785 | Hepatol Commun | Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity. | 2021 | Details |
| A29211 | 34411785 | Cell Mol Gastroenterol Hepatol | SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis. | 2021 | Details |
| A29227 | 34386991 | J Labelled Comp Radiopharm | Synthesis of tritium labeled 30-KDa PEG and conjugation to form [3 H]Pegbelfermin. | 2021 | Details |
| A29264 | 34341511 | Acta Pharmacol Sin | Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. | 2021 | Details |
| A29268 | 34329774 | Clin Gastroenterol Hepatol | Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. | 2021 | Details |
| A29306 | 34274514 | Clin Gastroenterol Hepatol | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. | 2021 | Details |
| A29319 | 34260795 | Hepatol Res | Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study. | 2021 | Details |
| A29320 | 34256254 | Bioorg Med Chem | Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio. | 2021 | Details |
| A29372 | 34166721 | J Hepatol | EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. | 2021 | Details |
| A29375 | 34165993 | J Med Chem | Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics. | 2021 | Details |
| A29404 | 34130335 | Semin Liver Dis | Interleukin-17 in Liver Disease Pathogenesis. | 2021 | Details |
| A29423 | 34093242 | Front Physiol | Nobiletin Alleviates Non-alcoholic Steatohepatitis in MCD-Induced Mice by Regulating Macrophage Polarization. | 2021 | Details |
| A29432 | 34079394 | Hepat Med | Step by Step: Managing the Complications of Cirrhosis. | 2021 | Details |
| A29435 | 34073868 | Cancers (Basel) | Mitochondrial Dynamics and Liver Cancer. | 2021 | Details |
| A29441 | 34062281 | Cell Mol Gastroenterol Hepatol | Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. | 2021 | Details |
| A29453 | 34041469 | JHEP Rep | Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. | 2021 | Details |
| A29466 | 34025430 | Front Pharmacol | Cellular Mechanisms of Liver Fibrosis. | 2021 | Details |
| A29467 | 34025027 | J Clin Biochem Nutr | Exacerbation of liver dysfunction in non-alcoholic steatohepatitis patients during the coronavirus disease 2019 (COVID-19) pandemic. | 2020 | Details |
| A29479 | 34016612 | Diabetes Care | Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. | 2021 | Details |
| A29491 | 33992834 | Cell Mol Gastroenterol Hepatol | METTL3/METTL14 Transactivation and m6A-Dependent TGF-β1 Translation in Activated Kupffer Cells. | 2021 | Details |
| A29506 | 33967756 | Front Pharmacol | Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis. | 2021 | Details |
| A29509 | 33965587 | Cell Mol Gastroenterol Hepatol | Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis. | 2021 | Details |
| A29522 | 33946842 | Healthcare (Basel) | Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis. | 2021 | Details |
| A29544 | 33908271 | Am J Physiol Gastrointest Liver Physiol | Targeting myosin 1c inhibits murine hepatic fibrogenesis. | 2021 | Details |
| A29549 | 33900587 | Obes Surg | Safety and Efficacy of Bariatric Surgery in Advanced Liver Fibrosis. | 2020 | Details |
| A29555 | 33891996 | Cancer Lett | Examining the gut-liver axis in liver cancer using organoid models. | 2021 | Details |
| A29565 | 33872466 | Basic Clin Pharmacol Toxicol | 3D human liver spheroids for translational pharmacology and toxicology. | 2021 | Details |
| A29568 | 33863340 | J Nanobiotechnology | Nanomaterials and hepatic disease: toxicokinetics, disease types, intrinsic mechanisms, liver susceptibility, and influencing factors. | 2021 | Details |
| A29577 | 33844557 | Org Lett | Semisynthesis of CRV431. | 2021 | Details |